Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Freeport-McMoRan Inc (FCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Freeport-McMoRan Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $296.08 (market cap $8.04B), while Freeport-McMoRan Inc trades at $61.02 (market cap $89.06B). The key difference: Freeport-McMoRan Inc is far larger — about 11.1× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Freeport-McMoRan Inc pays a 0.97% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | FCX | |
|---|---|---|
Market Cap | $8.04B | $89.06B |
Sector | Health | Basic Materials |
52-Week High | $339.75 | $71.73 |
52-Week Low | $241.71 | $35.34 |
Enterprise Value | $7.85B | $95.72B |
Dividend Yield | — | 0.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
FCX trades at $59.98, down 2.51% today, with a bearish technical signal but strong fundamentals. Recent earnings beats and a 10.34% net income margin highlight operational strength. The stock faces near-term resistance at $61, with support at $59. Analysts maintain a $72.94 consensus target, reflecting 22% upside potential. Copper demand growth and expansion projects support long-term prospects.
Outlook remains positive driven by copper's structural supply-demand imbalance and FCX's cost leadership. Risks include commodity price volatility and execution challenges in new projects. Institutional sentiment is bullish with 59% buy ratings, though technical indicators suggest near-term consolidation. The dividend yield of 0.25% provides modest income support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →
